170 related articles for article (PubMed ID: 35862031)
1. A Silk-Based Platform to Stabilize Phenylalanine Ammonia-lyase for Orally Administered Enzyme Replacement Therapy.
d'Amone L; Trivedi VD; Nair NU; Omenetto FG
Mol Pharm; 2022 Dec; 19(12):4625-4630. PubMed ID: 35862031
[TBL] [Abstract][Full Text] [Related]
2. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
Levy HL; Sarkissian CN; Scriver CR
Mol Genet Metab; 2018 Aug; 124(4):223-229. PubMed ID: 29941359
[TBL] [Abstract][Full Text] [Related]
3. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
[TBL] [Abstract][Full Text] [Related]
4. Alternative therapies to address the unmet medical needs of patients with phenylketonuria.
Blau N; Longo N
Expert Opin Pharmacother; 2015 Apr; 16(6):791-800. PubMed ID: 25660215
[TBL] [Abstract][Full Text] [Related]
5. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
Bell SM; Wendt DJ; Zhang Y; Taylor TW; Long S; Tsuruda L; Zhao B; Laipis P; Fitzpatrick PA
PLoS One; 2017; 12(3):e0173269. PubMed ID: 28282402
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
[TBL] [Abstract][Full Text] [Related]
7. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria.
Kang TS; Wang L; Sarkissian CN; Gámez A; Scriver CR; Stevens RC
Mol Genet Metab; 2010 Jan; 99(1):4-9. PubMed ID: 19793667
[TBL] [Abstract][Full Text] [Related]
8. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
[TBL] [Abstract][Full Text] [Related]
9. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
[TBL] [Abstract][Full Text] [Related]
10. Preservation of high phenylalanine ammonia lyase activities in roots of Japanese Striped corn: a potential oral therapeutic to treat phenylketonuria.
López-Villalobos A; Lücker J; López-Quiróz AA; Yeung EC; Palma K; Kermode AR
Cryobiology; 2014 Jun; 68(3):436-45. PubMed ID: 24657198
[TBL] [Abstract][Full Text] [Related]
11. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.
Wang L; Gamez A; Sarkissian CN; Straub M; Patch MG; Han GW; Striepeke S; Fitzpatrick P; Scriver CR; Stevens RC
Mol Genet Metab; 2005; 86(1-2):134-40. PubMed ID: 16006165
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.
Sarkissian CN; Gámez A; Wang L; Charbonneau M; Fitzpatrick P; Lemontt JF; Zhao B; Vellard M; Bell SM; Henschell C; Lambert A; Tsuruda L; Stevens RC; Scriver CR
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20894-9. PubMed ID: 19095795
[TBL] [Abstract][Full Text] [Related]
13. Biochemical analysis of Centaurea depressa phenylalanine ammonia lyase (PAL) for biotechnological applications in phenylketonuria (PKU).
Babaoğlu Aydaş S; Şirin S; Aslim B
Pharm Biol; 2016 Dec; 54(12):2838-2844. PubMed ID: 27246528
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice.
Rossi L; Pierigè F; Carducci C; Gabucci C; Pascucci T; Canonico B; Bell SM; Fitzpatrick PA; Leuzzi V; Magnani M
J Control Release; 2014 Nov; 194():37-44. PubMed ID: 25151978
[TBL] [Abstract][Full Text] [Related]
15. Directed evolution of Anabaena variabilis phenylalanine ammonia-lyase (PAL) identifies mutants with enhanced activities.
Mays ZJ; Mohan K; Trivedi VD; Chappell TC; Nair NU
Chem Commun (Camb); 2020 May; 56(39):5255-5258. PubMed ID: 32270162
[TBL] [Abstract][Full Text] [Related]
16. Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase).
Goldfinger M; Zeile WL; Corado CR; O'Neill CA; Tsuruda LS; Laipis PJ; Cooper JD
Mol Genet Metab; 2017 Sep; 122(1-2):33-35. PubMed ID: 28506393
[TBL] [Abstract][Full Text] [Related]
17. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
[TBL] [Abstract][Full Text] [Related]
18. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
Sarkissian CN; Gámez A
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.
Sarkissian CN; Kang TS; Gámez A; Scriver CR; Stevens RC
Mol Genet Metab; 2011 Nov; 104(3):249-54. PubMed ID: 21803624
[TBL] [Abstract][Full Text] [Related]
20. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
